Quarterly ResultJun 3, 2026, 08:07 AM
Avalyn Pharma Reports Wider Q1 Loss; Raises $316M Post-Quarter
AI Summary
Avalyn Pharma Inc. reported a wider net loss of $26.9 million for the first quarter of 2026, up from $17.5 million in the prior year, driven by increased operating expenses, particularly in research and development. The company's cash position improved significantly due to a $15 million Term loan and substantial proceeds from its Initial Public Offering (IPO) completed in May 2026, which raised approximately $316.1 million. Despite the increased loss, the IPO provides significant financial runway.
Key Highlights
- Avalyn Pharma reported a net loss of $26.9 million for the three months ended March 31, 2026, compared to a net loss of $17.5 million for the same period in 2025.
- Total operating expenses increased to $27.9 million in Q1 2026 from $18.7 million in Q1 2025, primarily due to higher R&D costs.
- Cash and cash equivalents increased to $92.3 million as of March 31, 2026, from $52.3 million as of December 31, 2025.
- Marketable securities decreased to $30.8 million as of March 31, 2026, from $86.0 million as of December 31, 2025.
- The company secured a $15 million Term loan during the quarter.
- Avalyn Pharma completed its IPO on May 1, 2026, raising approximately $316.1 million in net proceeds.
Price Impact
More from AVLN